Last reviewed · How we verify
blank Baraclude tablets
Baraclude (entecavir) inhibits hepatitis B virus reverse transcriptase, blocking viral replication.
Baraclude (entecavir) inhibits hepatitis B virus reverse transcriptase, blocking viral replication. Used for Chronic hepatitis B infection in adults, Chronic hepatitis B infection in children and adolescents.
At a glance
| Generic name | blank Baraclude tablets |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | Nucleoside reverse transcriptase inhibitor (NRTI) |
| Target | Hepatitis B virus reverse transcriptase / HBV polymerase |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | FDA-approved |
Mechanism of action
Entecavir is a nucleoside analog that selectively inhibits HBV polymerase (reverse transcriptase), preventing the virus from copying its genetic material and reducing viral load. It has high specificity for HBV and minimal activity against other viruses, making it a targeted antiviral therapy for chronic hepatitis B infection.
Approved indications
- Chronic hepatitis B infection in adults
- Chronic hepatitis B infection in children and adolescents
Common side effects
- Headache
- Fatigue
- Dizziness
- Nausea
- Lactic acidosis (rare but serious)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- blank Baraclude tablets CI brief — competitive landscape report
- blank Baraclude tablets updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI